Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study

Abstract Ixekizumab (IXE), an IL-17 A inhibitor, demonstrated efficacy in clinical trials in patients with psoriatic arthritis (PsA), and favorable data have emerged from real-world evidence studies on psoriasis as well. However, real-world data specific to PsA remain limited. This study aims to ass...

詳細記述

書誌詳細

主要な著者:	Stefano Gentileschi, Riccardo Terribili, Carla Gaggiano, Elisa Fiorentini, Laura Cometi, Cosimo Cigolini, Fabio Massimo Perrotta, Silvia Scriffignano, Luca Di Cato, Anna Panaccione, Laura Niccoli, Fabrizio Cantini, Maurizio Benucci, Francesca Li Gobbi, Andrea Delle Sedie, Antonio Vitale, Ennio Lubrano, Bruno Frediani, Serena Guiducci
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Portfolio 2026-02-01
シリーズ:	Scientific Reports
主題:	Psoriatic arthritis Ixekizumab Interleukin-17 Real-world evidence
オンライン･アクセス:	https://doi.org/10.1038/s41598-026-37835-x
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!